Abstract

Our aim was to investigate the value of combined detection of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA 242 and CA 50 in diagnosis and assessment of prognosis in consecutive gastric cancer patients. Clinical data including preoperative serum CEA, CA 19-9, CA 242, and CA 50 values and information on clinical pathological factors were collected and analyzed retrospectively. Univariate and multivariate survival analyses were used to explore the relationship between tumor markers and survival. Positive rates of tumor markers CEA, CA 19-9, CA 242 and CA 50 in the diagnosis of gastric cancer were 17.7, 17.1, 20.4 and 13.8%, respectively, and the positive rate for all four markers combined was 36.6%. Patients with elevated preoperative serum concentrations of CEA, CA 19-9, CA 242 and CA 50, had late clinical tumor stage and significantly poorer overall survival. Five-year survival rates in patients with elevated CEA, CA 19-9, CA 242 and CA 50 were 28.1, 25.8, 27.0 and 24.1%, respectively, compared with 55.0, 55.4, 56.4 and 54.5% in patients with these markers at normal levels (p<0.01). In multivariate Cox proportional hazards analyses, an elevated CA 242 level was determined to be an independent prognostic marker in gastric cancer patients. Combined detection of four tumor markers increased the positive rate for gastric cancer diagnosis. CA 242 showed higher diagnostic value and CA 50 showed lower diagnostic value. In resectable gastric carcinoma, preoperative CA 242 level was associated with disease stage, and was found to be a significant independent prognostic marker in gastric cancer patients.

Highlights

  • Gastric cancer is the fourth leading cause of cancerrelated death worldwide (Ferlay et al, 2010)

  • This paper explores the diagnostic value of the combined detection of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 CA 242 and CA 50 in patients with resectable gastric cancer, and evaluates the association between levels of these markers, clinicopathologic features and prognostic information

  • The results indicate that the preoperative serum CA 242 value can serve as an independent prognostic marker for gastric cancer patients

Read more

Summary

Introduction

Gastric cancer is the fourth leading cause of cancerrelated death worldwide (Ferlay et al, 2010). Early detection plays an important role in the optimal treatment for gastric cancer patients. Most blood tumor markers have poor specificity and sensitivity, but the combined detection of tumor markers can effectively increase the diagnostic and prognostic accuracy in gastric cancer. Many studies have examined the use of tumor markers such as CEA and CA 19-9 in gastric cancer patients. Sisik et al (2013) found that there was significant correlation of CEA and CA 19-9 values with advanced stage in gastric cancer patients. CEA and CA 19-9 are still valuable markers for the prognosis of gastric cancer patients. This paper explores the diagnostic value of the combined detection of serum CEA, CA 19-9 CA 242 and CA 50 in patients with resectable gastric cancer, and evaluates the association between levels of these markers, clinicopathologic features and prognostic information

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call